SCHEMBL7260690

SCHEMBL7260690

COc1ccc(-c2cn(C)c3ccc(OC)cc3c2=O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.49
PLK4 O00444 1/20 0.47
NUAK1 O60285 1/20 0.47
SRC P12931 1/20 0.47
FLT4 P35916 1/20 0.47
KDR P35968 1/20 0.47
FLT3 P36888 1/20 0.47
TEK Q02763 1/20 0.47
HTR6 P50406 1/20 0.47
GSK3B P49841 6/20 0.46
JAK2 O60674 1/20 0.46
LCK P06239 1/20 0.46
IGF1R P08069 1/20 0.46
GSK3A P49840 1/20 0.46
CDK7 P50613 1/20 0.46
BTK Q06187 1/20 0.46
LRRK2 Q5S007 1/20 0.46
AURKB Q96GD4 1/20 0.46
PRKCA P17252 4/20 0.45
MTNR1A P48039 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7260661 0.92 ALDH1A1 (0.54) ADRB2GSK3BPRKCABRD4ALDH1A1
SCHEMBL7261288 0.88 ALDH1A1 (0.55) PLK4NUAK1SRCFLT4KDR
SCHEMBL7197086 0.79 GSK3B (0.51) ADRB2PLK4NUAK1SRCFLT4
SCHEMBL10616242 0.79 ALDH1A1 (0.49) ADRB2FLT3HTR6GSK3BJAK2
SCHEMBL11064105 0.78 ADRB2 (0.58) ADRB2HTR6GSK3BMTNR1AMTNR1B
SCHEMBL7257625 0.76 ALDH1A1 (0.55) PLK4NUAK1SRCFLT4KDR
SCHEMBL7502631 0.75 GSK3B (0.70) KDRGSK3BPRKCA
SCHEMBL7257567 0.75 EGFR (0.52) PLK4NUAK1SRCFLT4KDR
SCHEMBL7256796 0.75 EGFR (0.71) FLT3ALDH1A1KDM4EHPGDRAB9A
SCHEMBL11399722 0.74 ADRB2 (0.47) ADRB2HTR6GSK3BMTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6645983-B1 Heterocyclic imines such as 3-(4-methoxyphenyl)-1,4-dihydro-4 -quinolinone, used as anticarcinogenic agents having cytolysis efficiency; side effect reduction LABORATOIRE L. LAFON (FR) 2003-11-11 US disclosed
EP-1202971-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING 4-QUINOLONES LABORATOIRE L. LAFON (FR) 2002-05-08 EP disclosed
WO-2002022074-A2 USE OF 2- AND 4- QUINOLONES FOR INHIBITING INTIMAL NEO-PROLIFERATION LABORATOIRE L. LAFON (FR) 2002-03-21 WO disclosed
WO-2001012607-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING 4-QUINOLONES FOR TREATING CANCERS LABORATOIRE L. LAFON (FR) 2001-02-22 WO disclosed